<DOC>
	<DOC>NCT01173536</DOC>
	<brief_summary>This is a Phase I, single-center, three-arm, randomized, double-blind, active- and placebo-controlled study to investigate the effect of GDC-0449 on the QT/QTc interval in healthy female subjects of non-childbearing potential.</brief_summary>
	<brief_title>A Study to Investigate the Effect of GDC-0449 on the QT/QTc Interval in Healthy Female Subjects</brief_title>
	<detailed_description />
	<mesh_term>Moxifloxacin</mesh_term>
	<criteria>Female, over 45 years of age In good health, as determined by the absence of clinically significant findings from the screening visit Body mass index between 18 and 32 kg/m^2 inclusive, with a body weight &gt; 45 kg Of nonchildbearing potential History of any clinically significant gastrointestinal, renal, hepatic, bronchopulmonary, neurological, psychiatric, cardiac, vascular, endocrinological, hematological, or allergic disease; metabolic disorder; cancer; or cirrhosis Allergy to moxifloxacin or any quinolone antibiotics or any confirmed significant allergic reactions against any drug, or multiple allergies in the judgment of the investigator Personal or family history of congenital long QT syndrome or family history of sudden death Participation in an investigational drug or device study with an investigational drug within the last 3 months or six times the elimination halflife, whichever is longer, prior to Day 1 of the study</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>